2009
The NIH entitlement program
DeVita V. The NIH entitlement program. Nature Reviews Clinical Oncology 2009, 6: 613-613. PMID: 19861989, DOI: 10.1038/nrclinonc.2009.164.Peer-Reviewed Original Research
1997
The war on cancer has a birthday, and a present.
DeVita V. The war on cancer has a birthday, and a present. Journal Of Clinical Oncology 1997, 15: 867-9. PMID: 9060521, DOI: 10.1200/jco.1997.15.3.867.Peer-Reviewed Original Research
1987
PDQ: an innovation in information dissemination linking cancer research and clinical practice.
Hubbard S, DeVita V. PDQ: an innovation in information dissemination linking cancer research and clinical practice. Important Advances In Oncology 1987, 263-77. PMID: 3331383.Peer-Reviewed Original Research
1984
On special initiatives, critics, and the National Cancer Program.
DeVita V. On special initiatives, critics, and the National Cancer Program. Journal Of The National Cancer Institute 1984, 68: 1-4. PMID: 6692421.Peer-Reviewed Original ResearchContrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.
DeVita V. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports. Journal Of The National Cancer Institute 1984, 68: 339-40. PMID: 6692433.Peer-Reviewed Original Research
1983
The Cancer Series: An Introduction
Devita V. The Cancer Series: An Introduction. Hospital Practice 1983, 18: 15-19. PMID: 6404774, DOI: 10.1080/21548331.1983.11702504.Peer-Reviewed Original ResearchCancer prevention NCI's primary goal.
Devita V. Cancer prevention NCI's primary goal. U.S. Medicine 1983, 19: 77-8. PMID: 10259324.Peer-Reviewed Original Research
1980
General Progress in Clinical Chemotherapy of Advanced Disease
Muggia F, Henney J, DeVita V. General Progress in Clinical Chemotherapy of Advanced Disease. Recent Results In Cancer Research 1980, 74: 1-7. PMID: 7003657, DOI: 10.1007/978-3-642-81488-4_1.Peer-Reviewed Original ResearchConceptsAggressive systemic treatmentMinimal residual diseaseTumor cell cytotoxicityAdvanced diseaseImmunologic factorsSystemic treatmentLocal therapyAdvanced cancerTumor burdenResidual diseaseTumor controlCurative approachLocoregional drug deliveryClinical chemotherapySuccessful chemotherapyEffective drugsDrug pharmacologyCell cytotoxicityInfectious diseasesDiseaseChemotherapyCancerCurrent resultsCellular heterogeneityTherapy
1978
The Evolution of Therapeutic Research in Cancer
DeVita V. The Evolution of Therapeutic Research in Cancer. New England Journal Of Medicine 1978, 298: 907-910. PMID: 634335, DOI: 10.1056/nejm197804202981610.Peer-Reviewed Original Research
1964
SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213).
OLIVERIO V, DENHAM C, DEVITA V, KELLY M. SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213). Cancer Chemotherapy Reports 1964, 42: 1-7. PMID: 14226125.Peer-Reviewed Original Research